Found 2 bookmarks
Custom sorting
The science of this Aug 2024 paper about was known clinically in Jan 2020 (attached paper).
The science of this Aug 2024 paper about was known clinically in Jan 2020 (attached paper).

The science of this Aug 2024 paper about #Covid was known clinically in Jan 2020 (attached paper).

If doctors had just read the literature & altered their treatment, millions of people would not have died.

When fibrin is being formed in the body a protein called D-dimer is made and can be measured in a blood sample.

This paper first published January 30, 2000 found D-dimer increased in 36% of patients, the sickest.

·x.com·
The science of this Aug 2024 paper about was known clinically in Jan 2020 (attached paper).
The Main protease (Mpro) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII
The Main protease (Mpro) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII
“Although the connection between COVID-19 and coagulopathy has been clear since the early days of SARS-CoV-2 pandemic, the underlying molecular mechanisms remain unclear. Available data support that the burst of cytokines and bradykinin, observed in some COVID-19 patients, sustains systemic inflammation and the hypercoagulant state, thus increasing thrombotic risk. Here we show that the SARS-CoV-2 main protease (Mpro) can play a direct role in the activation of the coagulation cascade.”
Although the connection between COVID-19 and coagulopathy has been clear since the early days of SARS-CoV-2 pandemic, the underlying molecular mechanisms remain unclear. Available data support that the burst of cytokines and bradykinin, observed in some COVID-19 patients, sustains systemic inflammation and the hypercoagulant state, thus increasing thrombotic risk. Here we show that the SARS-CoV-2 main protease (Mpro) can play a direct role in the activation of the coagulation cascade.
·biorxiv.org·
The Main protease (Mpro) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII